However, one needs to keep in mind that due to the protective effect of the US treatment, US-treated ALS mice were older at the symptomatic stage (10% weight loss, end of the early phase, mean ± SD for US: 155.6 days ±9.3 and Control: 145 days ±10, p = 0.016; US IGF1: 152.7 days ±6.8 and IGF1: 142.1 days ±8.5, p = 0.0081, ANOVA followed by a post hoc Šídák multiple comparison test) and disease end stage than their respective controls (Fig. 3b), showing slower disease progression. This evidence concerns the gene IGF1 and amyotrophic lateral sclerosis.